Advertisement

Topics

Kensey Nash Company Profile

05:17 EST 19th January 2019 | BioPortfolio

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occluded arteries.
The company was co-founded by Dr. Geoffrey Hartzler, pioneer of multi-vessel percutaneous transluminal coronary intervention (PTCI) and a recognized leader in the area of interventional cardiology. Incorporated in October 1997, the company is located in Carlsbad, California.

Location

735 Pennsylvania Drive
Exton
Pennsylvania
19341
United States of America

Contact

Phone: (484) 713-2100
Fax: (484) 713-2900
Email: Safecrossquestions@kenseynash.com


News Articles [301 Associated News Articles listed on BioPortfolio]

Is NASH Really a $35 Billion Opportunity?

Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalc...

Drs. Jonathan and Kenneth Nash Treat Gum Disease in Vicksburg, MS with Modern Laser Dentistry, Honor National Gum Care Month

VICKSBURG, MS (PRWEB) September 13, 2018 Nash Family Dentistry team, Drs. Jonathan Nash and Kenneth Nash, are honoring National Gum ...

Genentech buys NASH biotech Jecure

Roche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in inflammatory diseases including the fatty liver disease NASH. Non-alcoholi...

NASH market forecast to be worth $18.3bn by 2026

Due to increasing rates of obesity and diabetes, non-alcoholic steatohepatitis (NASH), a chronic inflammatory liver disease, is becoming increasingly prevalent....Read More... The post NASH market for...

Novartis, Pfizer Partner for NASH

A complex condition with no available treatment options, NASH affects up to 6.5% of the population worldwide

New partners for NASH

This year’s AASLD Liver meeting contains data on new NASH mechanisms for pharmas to consider picking up, but little clarity on combination strategy.

Merck licenses diabetes, NASH treatment from NGM

It's the latest example of pharma's growing interest in NASH, a condition expected to soon become a leading cause for liver transplants in the U.S.

NASH Cirrhosis: The Real NASH Epidemic

PubMed Articles [132 Associated PubMed Articles listed on BioPortfolio]

Treatment of NASH with Gastric Bypass.

Nonalcoholic steatohepatitis (NASH) is a spectrum of nonalcoholic fatty liver disease (NAFLD). It is defined as the presence of fatty liver along with inflammation and hepatocyte injury. To date, weig...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

The future R&D landscape in non-alcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no a...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.

Nonalcoholic steatohepatitis (NASH) might progress to fibrosis, cirrhosis, and hepatocellular carcinoma. However, the natural history of NASH has not been fully clarified. This study aimed to investig...

Clinical Trials [172 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [31 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

More Information about "Kensey Nash" on BioPortfolio

We have published hundreds of Kensey Nash news stories on BioPortfolio along with dozens of Kensey Nash Clinical Trials and PubMed Articles about Kensey Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Companies in our database. You can also find out about relevant Kensey Nash Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...


Corporate Database Quicklinks



Searches Linking to this Company Record